Clinical Trial Update: Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing intrapleural bevacizumab with Endostar for pleural effusions in non-small cell lung cancer; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Endostar (recombinant human endostatin)

Snippet

Sponsor: Zhejiang University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN